Neos Therapeutics, Inc, a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD) announced that the U.S. FDA approved Adzenys XR-ODT for the treatment of ADHD in patients six years and older.
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.
French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious diseases.
Cellceutix, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development.
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer. Public release of a data set of this scale is unprecedented and is intended to help advance research into combination cancer therapy across the global scientific community.
Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India.
US-based pharmaceutical firm Mission Pharmacal has launched a new safe and effective protective oral spray called Aquoral that moistens and lubricates the mouth for up to four hours.